전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved261 programs
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CD123 dual-target CAR-T module (Autologous CD33/CD123 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD33/CLL1 dual-target CAR-T module (Autologous CD33/CLL1 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD33

#CD33#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBaylor College of MedicinePhase 1

Autologous CD5.CAR/28zeta CAR T cells (Autologous CD5.CAR/28zeta CAR T cells)

T-cell Acute Lymphoblastic Lymphoma; T-non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Lymphoma

#T-cellAcuteLymphoblasticLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD5/CD7 dual-target CAR-T module (Autologous CD5/CD7 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleNavire Pharma Inc., a BridgeBio…Phase 1

nivolumab (Opdivo, BBP-398 with nivolumab)

Non Small Cell Lung Cancer; Solid Tumor · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
AntibodyLimited DatastaleNational Cancer Center, KoreaPhase 2

nivolumab (Opdivo, CA and Nivolumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#National
Trials 1Status Active
AntibodyLimited DatastaleGenzyme, a Sanofi CompanyPhase 2

alemtuzumab (CAMPATH, CAMPATH (alemtuzumab))

Non-Hodgkin's Lymphoma · Non-Hodgkin's Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#Genzyme
Trials 1Status Discontinued
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 1

CAR T cells chimeric antigenreceptor cells (CAR T cells chimeric antigenreceptor cells)

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma; Relapsed/Refractory B-cell ALL · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

CAR-NK (CAR-NK)

Pancreatic Cancer Non-resectable · Pancreatic Cancer Non-resectable

#PancreaticCancerNon-resectable#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleHebei Taihe Chunyu Biotechnolog…Phase 2

CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc） (CAR-T Cells infusion（CAR2219,CAR2019, CAR19 etc）)

Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL); AML (Acute Myelogenous Leukemia) · Lymphoma, B-cell, Aggressive Non-Hodgkin

#LymphomaB-cellAggressiveNon-Hodg#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleInstitute of Hematology & Blood…Phase 1

CAR-T cells chimenric antigen receptor T cells (CAR-T cells chimenric antigen receptor T cells)

B-Cell Non-Hodgkin Lymphoma · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleGuangzhou Anjie Biomedical Tech…Phase 2

CAR-T combining PD-1 Knockout (CAR-T combining PD-1 Knockout)

Lung Neoplasm Malignant; Non-small Cell Lung Cancer · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleThe Pregene (ShenZhen) Biotechn…Phase 1

CAR19 T cells carrying cytoplasmic activated PD-1 (CAR19 T cells carrying cytoplasmic activated PD-1)

Relapsed Non Hodgkin Lymphoma · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleKite, A Gilead CompanyPhase 1

CART-TnMUC1 (CART-TnMUC1)

Non-Small Cell Lung Cancer; Ovarian Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleChinese PLA General HospitalPhase 2

CART30 (CART30)

Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma · Hodgkin's Lymphoma

#HodgkinsLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital, Sch…Phase 1

CB dualCAR-NK19/70 (CB dualCAR-NK19/70)

B-cell Non Hodgkin Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastalePeking University People's Hosp…Phase 1

CD147- CAR T cells (CD147- CAR T cells)

T-cell Non-Hodgkin's Lymphoma · T-cell Non-Hodgkin's Lymphoma

#T-cellNon-HodgkinsLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastalePersonGen BioTherapeutics (Suzh…Preclinical

CD19 CAR-T cells infusion (CD19 CAR-T cells infusion)

Non Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleNationwide Children's HospitalPhase 1

CD19 specific Chimeric Antigen Receptor T Cell (CD19 specific Chimeric Antigen Receptor T Cell)

Acute Lymphoblastic Leukemia, in Relapse; Non-Hodgkin's Lymphoma, Relapsed · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleMedical University of South Car…Phase 2

CD19-CD34t metabolically programmed CAR transduced T-cells (CD19-CD34t metabolically programmed CAR transduced T-cells)

B-cell Non Hodgkin Lymphoma; Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

7 / 14 pages

← PreviousNext →